Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

June 10, 2025

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

June 3, 2025

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

March 31, 2025

Enveric Biosciences Participating in BIO-Europe Spring®

March 17, 2025

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

March 6, 2025

Enveric Biosciences CEO Issues Letter to Shareholders

February 27, 2025

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

February 25, 2025

1
2
3
…
15
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.